Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 8 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,548 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 7 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 6 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 5 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 4 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,379 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 3 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 2 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,716 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:40 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000124 · wf-form4_161852278913247.xml · derivative · entry 1 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 8 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,548 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 7 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
GrantShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 6 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 5 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 4 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,379 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 3 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
GrantShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 2 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,716 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:29 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000117 · wf-form4_161852214220847.xml · derivative · entry 1 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 8 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,548 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 7 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
GrantShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 6 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 5 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 4 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,379 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 3 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
GrantShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 2 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,716 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:43 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000127 · wf-form4_161852298714492.xml · derivative · entry 1 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:48 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights C · Derivative | 263,824 | $0.00 Strike: $25.68 | $0.00 |
DisclosureSEC source: 0001570585-21-000131 · wf-form4_161852326091960.xml · derivative · entry 4 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,824 Underlying: Class C Ordinary Shares · 263,824 shares Expires 2031-04-13 F3 · derivative.exercise_date: The Share Appreciation Rights vest 50% on May 1, 2023 and 50% on May 1, 2024. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:48 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights A · Derivative | 131,912 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001570585-21-000131 · wf-form4_161852326091960.xml · derivative · entry 3 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,912 Underlying: Class A Ordinary Shares · 131,912 shares Expires 2031-04-13 F3 · derivative.exercise_date: The Share Appreciation Rights vest 50% on May 1, 2023 and 50% on May 1, 2024. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:48 UTC |
Waldron JasonSVP & CAO
|
GrantRestricted Share Units C · Derivative | 31,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001570585-21-000131 · wf-form4_161852326091960.xml · derivative · entry 2 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,134 Underlying: Class C Ordinary Shares · 31,134 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be. F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2022. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2022. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:48 UTC |
Waldron JasonSVP & CAO
|
GrantRestricted Share Units A · Derivative | 15,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001570585-21-000131 · wf-form4_161852326091960.xml · derivative · entry 1 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,567 Underlying: Class A Ordinary Shares · 15,567 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be. F1 · price: Each Restricted Share Unit (RSU) represents a right to receive one share of Issuer's Class A ordinary shares or Class C ordinary shares, as the case may be. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments commencing on May 1, 2022. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments commencing on May 1, 2022. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
GrantShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 8 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,548 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 7 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
GrantShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 6 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 5 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
GrantShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 4 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,379 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 3 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
GrantShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 2 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,716 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:38 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000122 · wf-form4_161852266020015.xml · derivative · entry 1 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
GrantShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 8 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,548 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 8,548 | Not disclosed Strike: $41.41 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 7 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 8,548 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
GrantShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 6 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,303 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2025-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 4,303 | Not disclosed Strike: $44.46 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 5 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,303 shares Expires 2022-06-25 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
GrantShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 4 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,379 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,379 | Not disclosed Strike: $33.06 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 3 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,379 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
GrantShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 2 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,716 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2024-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:34 UTC |
COLE ANDREWDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,716 | Not disclosed Strike: $34.44 | Not disclosed |
DisclosureSEC source: 0001570585-21-000120 · wf-form4_161852246788270.xml · derivative · entry 1 COLE ANDREW · CIK 0001439731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,716 shares Expires 2021-06-26 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:46 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights C · Derivative | 84,490 | Not disclosed Strike: $40.52 | Not disclosed |
DisclosureSEC source: 0001570585-21-000130 · wf-form4_161852319834097.xml · derivative · entry 12 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,490 Underlying: Class C Ordinary Shares · 84,490 shares Expires 2025-05-01 F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:46 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights C · Derivative | 84,490 | Not disclosed Strike: $40.52 | Not disclosed |
DisclosureSEC source: 0001570585-21-000130 · wf-form4_161852319834097.xml · derivative · entry 11 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 84,490 shares Expires 2022-05-01 F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:46 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights A · Derivative | 41,903 | Not disclosed Strike: $42.01 | Not disclosed |
DisclosureSEC source: 0001570585-21-000130 · wf-form4_161852319834097.xml · derivative · entry 10 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,903 Underlying: Class A Ordinary Shares · 41,903 shares Expires 2025-05-01 F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:46 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights A · Derivative | 41,903 | Not disclosed Strike: $42.01 | Not disclosed |
DisclosureSEC source: 0001570585-21-000130 · wf-form4_161852319834097.xml · derivative · entry 9 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 41,903 shares Expires 2022-05-01 F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:46 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
GrantShare Appreciation Rights C · Derivative | 107,043 | Not disclosed Strike: $30.81 | Not disclosed |
DisclosureSEC source: 0001570585-21-000130 · wf-form4_161852319834097.xml · derivative · entry 8 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,043 Underlying: Class C Ordinary Shares · 107,043 shares Expires 2024-05-01 F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:46 UTC |
HALL BRYAN HEVP, Gen Counsel & Secretary
|
Disposition to issuerShare Appreciation Rights C · Derivative | 107,043 | Not disclosed Strike: $30.81 | Not disclosed |
DisclosureSEC source: 0001570585-21-000130 · wf-form4_161852319834097.xml · derivative · entry 7 HALL BRYAN H · CIK 0001292152 · EVP, Gen Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 107,043 shares Expires 2021-05-01 F4 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F4 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding share appreciation rights were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new share appreciation right is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F5 · derivative.exercise_date: Vesting and exercise of the existing share appreciation right has not changed as a result of the extension and therefore the share appreciation right continues to be immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.